Revenue
2021
Cardiol Therapeutics Inc. (CRDL)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $78,760 | — |
| Research & development | $14.0M | $14.0M | $14.2M | $19.0M | $10.9M | $10.6M |
| Operating income | −$34.3M | −$40.3M | −$29.8M | −$41.3M | −$38.7M | −$20.7M |
| EBITDAderived | — | −$39.9M | −$29.5M | −$41.1M | −$38.4M | −$20.5M |
| Net income | −$33.8M | −$36.7M | −$28.1M | −$30.9M | −$31.6M | −$20.6M |
| Basic EPSper diluted share | -CA$0.39 | -CA$0.51 | -CA$0.44 | -CA$0.49 | -CA$0.73 | -CA$0.69 |
| Diluted EPSper diluted share | -CA$0.39 | -CA$0.51 | -CA$0.44 | -CA$0.49 | -CA$0.73 | -CA$0.69 |